When would you consider aspirin for long term management of unprovoked VTE after initial therapeutic anticoagulation?

The WARFASA study suggests some benefit of aspirin in preventing recurrence. Would you consider it only in high bleeding risk patients, or even consider it for those reluctant to be on long-term anticoagulation?

Answer from: at Academic Institution

The WARFASA trial randomly assigned patients with first unprovoked VTE who had completed 6-18 months of anticoagulation to 2 additional years of aspirin versus placebo. While the study demonstrated a 40% reduction in recurrent thrombotic events, the rates of VTE in those receiving aspirin were still...

Comments

Medical Oncologist at Medical University of South Carolina
An important point about similar bleeding risk

Please select the option that best describes you:

When would you consider aspirin for long term management of unprovoked VTE after initial therapeutic anticoagulation?

Related Questions